All In Biotech

Drug Trial Radar · NCT01942122

DLBS1442 for The Treatment of Pain in Patients Suspected Endometriosis

Role of DLBS1442 for The Treatment of Pain in Patients Suspected Endometriosis

Last checked: Nov 19, 2026Latest source record: Jan 27, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

60

Actual

Start

Oct 2015

Primary completion

Feb 2021

Study completion Apr 2021

Sponsor

Lead sponsor
Dexa Medica GroupIndustry
Sponsor type
Industry
First posted
Sep 13, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Female only, from 18 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 3-arm, prospective, randomized, double-blind, and controlled study of DLBS1442 for the treatment of pain in patients suspected endometriosis. It is hypothesized that the reduction of the composite-pain intensity (as measured by VAS) from baseline to the end of study (week 8th) resulting from administration of DLBS1442, regardless of the dosage regimen, is significantly greater than that of Control. In addition, the administration of DLBS1442 at higher dose also results in significantly greater reduction than that of DLBS1442 at lower dose and of Control.

Conditions

  • Endometrioma
  • Visual Analogue Pain Scale: Moderate or Severe Pain

Interventions

  • DLBS1442 100Drug

    Study treatment will be DLBS1442 capsules at a dose of 3x100 mg daily. DLBS1442 will be taken every day for 8 weeks (2 menstrual cycles).

  • Mefenamic acidDrug

    Control will be mefenamic acid 500 mg tablets, administered 3 times daily for 5 days during the menstrual period, i.e. day 1st to day 5th of the menstrual period. The drug will be given within the 8 weeks of study period (2 menstrual cycles).

  • DLBS1442 200Drug

    Study treatment will be DLBS1442 capsules at a dose of 3x200 mg daily. DLBS1442 will be taken every day for 8 weeks (2 menstrual cycles).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Reduction of intensity (VAS) of composite-painTime frame: Week 8

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Department of Obstetrics and Gynecology RSUP Fatmawati

    Jakarta, Indonesia

  • Yasmin Clinic, Dr. Cipto Mangunkusumo Hospital (Kencana)

    Jakarta Pusat, Jakarta Special Capital Region, Indonesia

  • Department of Obstetrics and Gynecology, RSUP Persahabatan

    Jakarta Pusat, Jakarta Special Capital Region, Indonesia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.